Peter Thiel discloses 4.6% Chemomab (NASDAQ: CMMB) ownership

Rhea-AI Filing Summary

Peter Thiel and Rivendell Investments 2017-9 LLC report a 4.6% passive stake in Chemomab Therapeutics Ltd. on Schedule 13G/A. They beneficially own 22,631,200 ordinary shares as of December 31, 2025, based on 492,409,320 shares outstanding as of September 30, 2025.

The position is held through American Depositary Shares and a warrant: 22,170,160 ordinary shares represented by 277,127 ADSs and 461,040 ordinary shares represented by 5,763 ADSs issuable upon warrant exercise. Each ADS represents 80 ordinary shares. The filers state the securities are not held to change or influence control.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:48 PM Learn about SEC filing dates

FAQ

What does the Chemomab (CMMB) Schedule 13G/A filing report?

The Schedule 13G/A reports that Peter Thiel and Rivendell Investments 2017-9 LLC beneficially own 22,631,200 Chemomab ordinary shares, equal to 4.6% of the company, and that the stake is reported on a passive basis without a stated intent to influence control.

How large is Peter Thiel’s ownership stake in Chemomab (CMMB)?

Peter Thiel and Rivendell Investments 2017-9 LLC together beneficially own 22,631,200 Chemomab ordinary shares, representing 4.6% of the class. This percentage is calculated using 492,409,320 shares outstanding as of September 30, 2025, as disclosed in a Chemomab Form 6-K.

How is the Chemomab (CMMB) stake held by Rivendell Investments structured?

Rivendell Investments 2017-9 LLC holds 22,170,160 Chemomab ordinary shares via 277,127 American Depositary Shares and 461,040 ordinary shares via 5,763 ADSs issuable on warrant exercise. Each ADS represents 80 ordinary shares, combining current ADS holdings and warrant-linked ADSs.

What type of securities are covered in the Chemomab (CMMB) 13G/A?

The filing covers Chemomab ordinary shares with no par value, primarily represented by American Depositary Shares with CUSIP 16385C203. Each ADS equals 80 ordinary shares, and a portion of the reported beneficial ownership is tied to ADSs issuable upon warrant exercise held by Rivendell.

Do Peter Thiel and Rivendell seek control of Chemomab (CMMB)?

The filers certify that the Chemomab securities were not acquired and are not held to change or influence control of the issuer. They state the holdings are not part of any transaction aimed at control, other than activities solely related to a specific nomination rule reference.

Why does the Chemomab (CMMB) filing mention ownership of 5 percent or less?

The filing notes ownership of 5 percent or less of the class, consistent with the reported 4.6% stake. This indicates the reporting persons’ holdings fall below the 5% threshold and explains why the Schedule 13G/A reflects a sub‑5% beneficial ownership position in Chemomab.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Chemomab Therapeutics Ltd.

(Name of Issuer)

Ordinary shares, no par value per share

(Title of Class of Securities)

16385C203

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 16385C203

1

Names of Reporting Persons

Peter Thiel

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 22,631,200.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 22,631,200.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

22,631,200.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.6 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 16385C203

1

Names of Reporting Persons

Rivendell Investments 2017-9 LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 22,631,200.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 22,631,200.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

22,631,200.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.6 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Chemomab Therapeutics Ltd.
(b)	Address of issuer's principal executive offices: 10 Habarzel Street, Building C, 10th Floor, TEL AVIV, L3, 6158002.
Item 2.
(a)	Name of person filing: This Statement on Schedule 13G has been filed on behalf of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"): 1. Rivendell Investments 2017-9 LLC 2. Peter Thiel
(b)	Address or principal business office or, if none, residence: The address of Rivendell Investments 2017-9 LLC is 1209 Orange Street, Wilmington, Delaware 19801. The address of Peter Thiel is c/o Thiel Capital LLC, 215 NW 24th St., Suite 801, Miami, FL 33127.
(c)	Citizenship: See Row 4 of cover page for each Reporting Person.
(d)	Title of class of securities: Ordinary shares, no par value per share
(e)	CUSIP No.: 16385C203
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: There is no CUSIP number assigned to the ordinary shares. CUSIP number 16385C203 has been assigned to the American Depositary Shares ("ADSs") of the Issuer. Each ADS represents 80 ordinary shares, Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of ordinary shares (the "Shares") of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of (i) 22,170,160 Shares that are represented by 277,127 ADSs of the Issuer held by Rivendell Investments 2017-9 LLC and (ii) 461,040 Shares that are represented by 5,763 ADSs issuable upon exercise of a warrant held by Rivendell Investments 2017-9 LLC.
(b)	Percent of class: Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the Shares of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. The percentage set forth in each row 11 is based upon 492,409,320 Shares outstanding as of September 30, 2025, as reported in the Issuer's Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission (the "SEC") on November 21, 2025.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference.
	(ii) Shared power to vote or to direct the vote: Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference.
	(iii) Sole power to dispose or to direct the disposition of: Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference.
	(iv) Shared power to dispose or to direct the disposition of: Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. The Reporting Persons are filing this Schedule 13G jointly, but not as members of a group, and each expressly disclaims membership in a group.
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Peter Thiel

Signature:	/s/ Peter Thiel
Name/Title:	Peter Thiel
Date:	02/17/2026

Rivendell Investments 2017-9 LLC

Signature:	/s/ Peter Thiel
Name/Title:	By Peter Thiel, Authorized Signatory
Date:	02/17/2026

Exhibit Information

Exhibit 1 Joint Filing Agreement dated March 26, 2021 among the reporting persons (incorporated by reference to Exhibit 1 of Schedule 13G (File No. 005-86953) filed March 26, 2021).